Perceptive Discovery and Nucleus RadioPharma have announced a non-exclusive strategic partnership to assist radiopharmaceutical developers shift from initial target validation through to clinical manufacturing.
Made Scientific has acquired an 85,000ft² cell therapy manufacturing facility in Pennsylvania, US, from National Resilience, adding an operational site to its US East Coast network.
Cheplapharm has entered a strategic partnership to take over a portfolio of 20 mature medicines, along with three manufacturing facilities globally, from Sanofi.
ABEC is set to open a new manufacturing facility in Wilson, North Carolina, US, expanding its network for biopharmaceutical process equipment and consumables.
AtomVie Global Radiopharma has opened a purpose-built radiopharmaceutical manufacturing facility in Hamilton, Ontario, Canada, with an investment of more than $160m.
Andelyn Biosciences is set to develop and manufacture a gene therapy known as AAV9-GM2, for Queen’s University to treat GM2 gangliosidoses, including Tay-Sachs and Sandhoff diseases.
Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth.
Resilience and Eli Lilly and Company have expanded their partnership with a joint $750m investment to increase the production of Lilly’s KwikPen injectable device in Ohio, aiming to strengthen the supply of diabetes and obesity medicines in the US.
Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn).
Intravacc has signed an exclusive licensing agreement with Beijing Zhifei Lvzhu Biopharmaceutical (Zhifei Lvzhu) in China for Avacc 3, an OMV-based whooping cough vaccine.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.